OSR Health, Inc.
Close on Oct 19, 2026
- Market cap
- $6.83M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
OSR Health has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements OSR Health filed with the SEC
PRESS RELEASE ISSUED BY OSR HEALTH, INC., DATED AUGUST 19, 2026, TITLED "OSR HEALTH RECEIVES NASDAQ STAFF DELISTING DETERMINATION; INTENDS TO REQUEST HEARINGS PANEL APPEAL."
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 7, 2026, TITLED "OSR HEALTH ISSUES CLARIFICATION REGARDING PRIOR NASDAQ COMMUNICATION AND SHAREHOLDER LOYALTY CVR PROGRAM"
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 31, 2026, TITLED "OSR HEALTH SECURES NASDAQ COMMUNICATION: LOYALTY CVR PROGRAM WILL NOT TRIGGER A PRICE ADJUSTMENT"
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 29, 2026, TITLED "OSR HOLDINGS EXECUTES DEFINITIVE $815 MILLION GLOBAL LICENSE AGREEMENT FOR VXM01 WITH BCM EUROPE"
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 9, 2026, TITLED "OSR HOLDINGS ELIMINATES $2.02 MILLION WARRANT OVERHANG WITH PREMIUM-PRICED CONVERTIBLE NOTE"
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JANUARY 27, 2026, TITLED "OSR HOLDINGS COMPLETES WOORI IO ACQUISITION, SECURES LONG-TERM SHAREHOLDER ALIGNMENT, AND REVIEWS STRATEGIC COMBINATION OF MEDICAL DEVICE SUBSIDIARIES."
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JANUARY 12, 2026 TITLED "VAXIMM, AN OSR COMPANY, RECEIVES BINDING TERM SHEET FROM BCM EUROPE FOR GLOBAL EXCLUSIVE LICENSE OF VXM01 WITH $30M UPFRONT AND UP TO $815M IN MILESTONES"
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED NOVEMBER 21, 2025 TITLED "VAXIMM AG, AN OSR COMPANY, ENTERS TERM SHEET WITH BCM EUROPE FOR POTENTIAL VXM01 LICENSE WITH $20M UPFRONT AND UP TO $815M IN MILESTONES."
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED OCTOBER 14, 2025 TITLED ''OSR HOLDINGS SIGNS DEFINITIVE AGREEMENT TO ACQUIRE WOORI IO, A PIONEER IN NONINVASIVE GLUCOSE MONITORING WITH POTENTIAL TO TRANSFORM DIABETES CARE.''
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION DATED AUGUST 6, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY, 24, 2025, ANNOUNCING ENTRY INTO TERM SHEET WITH WOORI IO CO., LTD
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 14, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 13, 2025
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Bellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at May 14, 2024 Stockholder Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.
Material agreement · New financial obligation · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Bellevue Life Sciences Acquisition Corp. and OSR Holdings Sign an Exclusive Letter of Intent for a Business Combination
Regulation FD disclosure · EX-99.1 to Form 8-K
Bellevue Life Sciences Acquisition Corp. Announces Separate Trading of its Shares of Common Stock,
Other events · EX-99.1 to Form 8-K
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
Other events · EX-99.1 to Form 8-K
Bellevue Life Sciences Acquisition Corp. Announces Closing of Full Over-allotment Option
Executive or director change · Other events · EX-99.1 to Form 8-K
Bellevue Life Sciences Acquisition Corp. Announces Pricing of $60 Million Initial Public Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Bellevue Life Sciences Acquisition Corp. Announces Closing of $60 Million Initial Public Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K